Shockwave Medical Inc. (SWAV)
(Delayed Data from NSDQ)
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Should You Buy ShockWave Medical (SWAV) Ahead of Earnings?
by Zacks Equity Research
ShockWave Medical (SWAV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Shockwave Medical (SWAV) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Lantheus (LNTH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) third-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Shockwave Medical (SWAV) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Charles River (CRL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the third quarter.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
What's in Store for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) first-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.
Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stryker (SYK) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Stryker's (SYK) third-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.
Cencora (COR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) fiscal fourth-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Shockwave Medical (SWAV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Shockwave Medical (SWAV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued segmental strength.
Wall Street Analysts See a 27.54% Upside in Shockwave Medical (SWAV): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Shockwave Medical (SWAV) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Integer (ITGR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 20.95% and 8.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
NextGen (NXGN) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
NextGen's (NXGN) second-quarter fiscal 2024 results reflect strength in its Recurring revenues.
Shockwave Medical (SWAV) Announces IVL Studies' Positive Results
by Zacks Equity Research
Shockwave Medical's (SWAV) latest announcement of two new publications validates the utility of IVL in complex nodular and eccentric calcium.
Are Options Traders Betting on a Big Move in Shockwave Medical (SWAV) Stock?
by Zacks Equity Research
Investors need to pay close attention to Shockwave Medical (SWAV) stock based on the movements in the options market lately.
Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWO
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWG
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSMD
3 Intriguing Stocks to Buy After Earnings
by Shaun Pruitt
With various scenarios, these top-rated stocks are appealing after reporting their Q2 results on Monday and should have more upside as we progress through 2023.
Shockwave Medical (SWAV) Q2 Earnings Miss, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.